O
YARW

OrbiMed’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

OrbiMed’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-165
Closed -$1.03M – 160
2020
Q2 		$1.03M Sell
165
-321
-66% -$2.17M 0.01% 133
2020
Q1 		$4.69M Buy
+486
New +$7.62M 0.08% 109
2019
Q4 		– Sell
-184
Closed -$2.97M – 147
2019
Q3 		$2.97M Sell
184
-3
-2% -$48.4K 0.06% 104
2019
Q2 		$4.04M Buy
187
+11
+6% +$272K 0.06% 115
2019
Q1 		$4.98M Buy
+176
New +$4.22M 0.08% 108
2018
Q4 		– Sell
-131
Closed -$4.66M – 152
2018
Q3 		$4.66M Buy
+131
New +$4.04M 0.06% 130

Other funds holding YARW

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

OrbiMed's YARW Position: Q3 2020 in Review

OrbiMed sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q3 2020, closing a stake of 165 shares — an estimated $1.03M sold.

OrbiMed first reported a position in YARW in Q3 2018 and held it in 6 quarters. The position peaked at $4.98M in Q1 2019. 97 funds tracked by Wall St. Rank hold YARW as of Q3 2020.

  • OrbiMed reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • OrbiMed sold 165 Yarrow Bioscience, Inc. Common Stock shares in Q3 2020, an estimated $1.03M.
  • OrbiMed first reported a position in Yarrow Bioscience, Inc. Common Stock in Q3 2018 and held it in 6 quarters.
  • OrbiMed's Yarrow Bioscience, Inc. Common Stock position peaked at $4.98M in Q1 2019.
  • 97 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q3 2020.

Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.